Opinion|Videos|July 17, 2024
Differentiating Clinical Markers in Vitiligo: Managing Unstable Disease and Depigmented Macules
Author(s)Andrew F. Alexis, MD, MPH
An expert on vitiligo discusses the case of a 49-year-old woman with a history of vitiligo who presents with depigmented macules on her abdomen, thighs, and forearms that developed over 2 months.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What is your impression of this case?
- What challenges does this case present with, if any?
- What considerations should be taken into account when treating a patient with worsening vitiligo involving large BSA?
- In your clinical practice, what role does the amount of BSA coverage play in your treatment decisions?
- Are there BSA limits you adhere to when treating patients with widespread vitiligo?
- What is your approach to the patient with worsening vitiligo that involves high BSA?
Advertisement
Related to this article
Dermatology clinicians at a Case-Based Roundtable in Austin, Texas, discussed real-world strategies for sequencing topical therapy, phototherapy, and ruxolitinib cream across pediatric and adult vitiligo cases.
In TRANQUILLO 2, 21.86% of patients taking ritlecitinib 100 mg achieved F-VASI75 at week 52 vs 2.40% with placebo, according to data presented at EADV 2026.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
2
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
3
Topical vs Oral JAK Inhibitors for Vitiligo: How to Choose as Systemic Options Advance
4
Q&A: Falk G. Bechara, MD, on Long-Term Tunnel Control and Structural Damage in HS
5